Chemotherapy against human African trypanosomiasis: Is there a road to success?

Parasitology

Volumn 137, Issue 14, 2010, Pages 1987-1994

  Burri, Christian ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

DB289; drugs; eflornithine; fexinidazole; Human African trypanosomiasis; melarsoprol; NECT; pafuramidine maleate; pentamidine; sleeping sickness; suramin; treatment

Indexed keywords

ADRENALIN; APREPITANT; DEXAMETHASONE; DIAZEPAM; EFLORNITHINE; FEXINIDAZOLE; MANNITOL; MELARSOPROL; NIFURTIMOX; PAFURAMIDINE; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PENTAMIDINE MESYLATE; SURAMIN;

ABDOMINAL PAIN; AFRICA; AFRICAN TRYPANOSOMIASIS; AGITATION; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; ALOPECIA; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIPROTOZOAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW TOXICITY; BRAIN DISEASE; CLINICAL RESEARCH; COMBINATION CHEMOTHERAPY; CONVULSION; DIARRHEA; DRUG CEREBROSPINAL FLUID LEVEL; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXFOLIATIVE DERMATITIS; FUNDING; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; GRAND MAL SEIZURE; HEALTH PROGRAM; HEARING IMPAIRMENT; HEMATURIA; HEMOLYTIC ANEMIA; HIGH THROUGHPUT SCREENING; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; INJECTION SITE PAIN; KIDNEY DISEASE; KIDNEY INJURY; LEUKOPENIA; MONOTHERAPY; NAUSEA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PERIPHERAL PARALYSIS; PNEUMOCYSTOSIS; POLITICAL PARTICIPATION; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; SENSORY NEUROPATHY; SHOCK; SIDE EFFECT; SKIN LEISHMANIASIS; SKIN MANIFESTATION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREMOR; TRYPANOSOMA BRUCEI; TRYPANOSOMA GAMBIENSE; TRYPANOSOMA RHODESIENSE; URTICARIA; VOMITING;

AFRICA; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN;

TRYPANOSOMA BRUCEI;

EID: 78650306664     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182010001137     Document Type: Article

References (50)

1. ®. In Arzneimittel- Kompendium Der Schweiz (ed. Dokumed A. G., Basel., Switzerland).
2. Anonymous (2009). Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole. ClinicalTrials.gov (Clinical Trials Registry): http://www.clinicaltrials.gov/ct2/show/ NCT00982904?term= NCT00982904&rank=1 (Accessed 24 June 2010).
3. Balasegaram, M., Harris, S., Checchi, F., Ghorashian, S., Hamel, C. and Karunakara, U. (2006a). Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Bulletin of the World Health Organization 84, 783-791.
4. Balasegaram, M., Harris, S., Checchi, F., Hamel, C. and Karunakara, U. (2006b). Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Bulletin of the World Health Organization 84, 777-782.
5. Barrett, M. P., Boykin, D. W., Brun, R. and Tidwell, R. R. (2007). Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. British Journal of Pharmacology 152, 1155-1171.
6. Bayer (2002). Bayer sustainable development report 2004. Vol. 2008. http://www.bayer.com/en/sustainable- development-report-2004.pdfx (Accessed 29 July 2010).
7. Bisser, S., N'siesi, F. X., Lejon, V., Preux, P. M., Van Nieuwenhove, S., Miaka Mia Bilenge, C. and Buscher, P. (2007). Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. Journal of Infectious Diseases 195, 322-329.
8. Blum, J. A., Burri, C., Hatz, C., Kazumba, L., Mangoni, P. and Zellweger, M. J. (2007). Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis). Tropical Medicine and International Health 12, 1422-1432.
9. Bronner, U. (1994). Pharmacokinetics of pentamidine. Focus on treatment of Trypanosoma gambiense sleeping sickness. PhD Thesis, Karolinska Institute, Stockholm.
10. Bronner, U., Doua, F., Ericsson, O., Gustafsson, L., Miezan, T., Rais, M. and Rombo, L. (1991). Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire. Transactions of the Royal Society of Tropical Medicine and Hygiene 85, 608-611.
11. Burri, C. and Brun, R. (2003). Eflornithine for treatment of human African trypanosomiasis. Parasitology Research 90 (Suppl), S49-S52.
12. Burri, C. and Brun, R. (2008). Chapter 76: Human African trypanosomiasis. In Manson's Tropical Diseases (eds. Cook, G., and Zumla, A.), pp. 1307-1325. W.B. Saunders, London.
13. Burri, C., Nkunku, S., Merolle, A., Smith, T., Blum, J. and Brun, R. (2000). Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355, 1419-1425.
14. Burri, C., Stich, A. and Brun, R. (2004). Current chemotherapy of Human African sleeping sickness. In The Trypanosomiases (eds. Maudlin, I., Holmes, P., and Miles, M. A.), pp. 403-419. CABI, Wallingford.
15. Chappuis, F. (2007). Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go. Clinical Infectious Diseases 45, 1443-1445.
16. Chappuis, F., Udayraj, N., Stietenroth, K., Meussen, A. and Bovier, P. A. (2005). Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clinical Infectious Diseases 41, 748-751.
17. Checchi, F., Piola, P., Ayikoru, H., Thomas, F., Legros, D. and Priotto, G. (2007). Nifurtimox plus Eflornithine for late-Stage sleeping sickness in Uganda: A case series. PLoS Neglected Tropical Diseases 1, e64.
18. DNDi (2008a). NECT: Next steps. In DNDi Newsletter, 17.
19. DNDi (2008b). Fexinidazole progresses into clinical development. DNDi Newsletter, 17.
20. DNDi (2009). NECT added to WHO essential medicines list as combination treatment against sleeping sickness. DNDi Press Release. http://www.dndi.org/ press-releases/456-nect-added-to-who-essential-medicines-list-as-combination- treatment-against-sleeping-sickness.html (Accessed 24 June 2010)
21. DNDi (2010). NECT - Nifurtimox-Eflornithine: Co-Administration (HAT). http://www.dndi.org/ portfolio/nect.html (Accessed 24 June 2010)
22. Dorlo, T. P. and Kager, P. A. (2008). Pentamidine dosage: a base/salt confusion. PLoS Neglected Tropical Diseases 2, e225.
23. Doua, F., Miezan, T. W., Sanon Singaro, J. R., Boa Yapo, F. and Baltz, T. (1996). The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. American Journal of Tropical Medicine and Hygiene 55, 586-588.
24. Doua, F. and Yapo, F. B. (1993). Human trypanosomiasis in the Ivory Coast - therapy and problems. Acta Tropica 54, 163-168.
25. Gustafsson, L. L., Beerman, B. and Aden Abdi, Y. (1987). Suramin. In Handbook of Drugs for Tropical Parasitic infections (eds. Gustafsson, L. L., Beerman, B., and Aden Abdi, Y.), pp. 160-163. Taylor & Francis, Basingstoke.
26. IFPMA and International Federation of Pharmaceutical Manufacturers & Associations (2008). Health Partnerships for the Developing World -Sanofi-Aventis Sleeping Sickness Program. Vol. 2008.
27. Iten, M., Mett, H., Evans, A., Enyaru, J. C, Brun, R. and Kaminsky, R. (1997). Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha- difluoromethylornithine. Antimicrobial Agents and Chemotherapy 41, 1922-1925.
28. Jansson, R., Malm, M., Roth, C. and Ashton, M. (2008). Enantioselective and nonlinear intestinal absorption of eflornithine in the rat. Antimicrobial Agents and Chemotherapy 52, 2842-2848.
29. Kansiime, F., Adibaku, S., Wanboga, C, Iddi, F., Matovu, E., Yamuah, L. and Kioy, D. (2009). Clinical study of nifurtimox-eflornithine combination treatment (NECT) of late stage Trypanosoma brucei gambiense patients in NW Uganda: Implications for the National sleeping sickness control programme. In 30th Meeting of the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) (ed. OAU/STRC, Nairobi), p.69, Kampala, Uganda.
30. Kuepfer, I. (2009). Impamel III - Improved melarsoprol application for the treatment of second stage T. b. rhodesiense sleeping sickness. In 30th Meeting of the International Scientific Council for Trypanosomiasis Research and Control (ISCTRC) (ed. OAU/STRC, Nairobi), p. 70. Kampala, Uganda.
31. Lejon, V., Legros, D., Savignoni, A., Etchegorry, M. G., Mbulamberi, D. and Buscher, P. (2003). Neuro-inflammatory risk factors for treatment failure in "early second stage" sleeping sickness patients treated with Pentamidine. Journal of Neuroimmunology 144, 132-138.
32. Médecins Sans Frontières (2007). Clinical Guidelines. http://www.refbooks.msf-docs/en/Clinical-Guide/ CG-en.pdf (Accessed 29 July 2010).
33. Na-Bangchang, K., Doua, F., Konsil, J., Hanpitakpong, W., Kamanikom, B. and Kuzoe, F. (2004). The pharmacokinetics of eflornithine (alpha- difluoromethylornithine) in patients with late-stage T. b. gambiense sleeping sickness. European Journal of Clinical Pharmacology 60, 269-278.
34. Pepin, J., Khonde, N., Maiso, F., Doua, F., Jaffar, S., Ngampo, S., Mpia, B., Mbulamberi, D. and Kuzoe, F. (2000). Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bulletin of the World Health Organization 78, 1284-1295.
35. Pepin, J., Milord, F., Meurice, F., Ethier, L., Loko, L. and Mpia, B. (1992). High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Transactions of the Royal Society of Tropical Medicine and Hygiene 86, 254-256.
36. Pohlig, G., Bernhard, S., Blum, J., Burri, C., Mpanya Kabeya, A., Fina Lubaki, J.-P., Mpoo Mpoto, A., Fungula Munungu, B., Kambau Manesa Deo, G., Nsele Mutantu, P., Mbo Kuikumbi, F., Fukinsia Mintwo, A., Kayeye Munungi, A., Dala, A., Macharia, S., Miaka Mia Bilenge, C., Kande Betu Ku Mesu, V., Ramon Franco, J., Dieyi Dituvanga, N. and Olson, C. (2008). Phase 3 trial of pafuramidine maleate (DB289), a novel, oral drug, for treatment of first stage sleeping sickness: Safety and Efficacy. In 57th Meeting of the American Society of Tropical Medicine and Hygiene pp. Abstract No. 542. New Orleans.
37. Priotto, G., Fogg, C., Balasegaram, M., Erphas, O., Louga, A., Checchi, F., Ghabri, S. and Piola, P. (2006). Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Uganda. PLoS Clinical Trials 1, e39: 31-38.
38. Priotto, G., Kasparian, S., Mutombo, W., Ngouama, D., Ghorashian, S., Arnold, U., Ghabri, S., Baudin, E., Buard, V., Kazadi-Kyanza, S., Ilunga, M., Mutangala, W., Pohlig, G., Schmid, C., Karunakara, U., Torreele, E. and Kande, V. (2009). Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374, 56-64.
39. Priotto, G., Kasparian, S., Ngouama, D., Ghorashian, S., Arnold, U., Ghabri, S. and Karunakara, U. (2007). Nifurtimox-Eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Congo. Clinical Infectious Diseases 45, 1435-1442.
40. Priotto, G., Pinoges, L., Fursa, I. B., Burke, B., Nicolay, N., Grillet, G., Hewison, C. and Balasegaram, M. (2008). Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. British Medical Journal 336, 705-708.
41. Rodgers, J., Bradley, B. and Kennedy, P. G. (2007). Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis. Parasitology International 56, 321-324.
42. Ruiz, J. A., Simarro, P. P. and Josenando, T. (2002). Control of human African trypanosomiasis in the Quicama focus, Angola. Bulletin of the World Health Organization 80, 738-745.
43. Schmid, C., Richer, M., Bilenge, C. M., Josenando, T., Chappuis, F., Manthelot, C. R., Nangouma, A., Doua, F., Asumu, P. N., Simarro, P. P. and Burri, C. (2005). Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: Confirmation from a multinational study (Impamel II). Journal of Infectious Diseases 191, 1922-1931.
44. Seixas, J. (2004). Investigations on the encephalopathic syndrome during melarsoprol treatment of human African trypanosomiasis. PhD Thesis, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa.
45. Van Nieuwenhove, S. (1999). Present strategies in the treatment of human African trypanosomiasis. In Progress in Human African trypanosomiasis, Sleeping Sickness (eds. Dumas, M., Bouteille, B., and Buguet, A.), pp. 253-280. Springer, Paris.
46. Waddy, B. B. (1970). Chemoprophylaxis of human trypanosomiasis. In The African Trypanosomiases (ed. Mulligan, H. W.), pp. 711. Allan & Unwin, London.
47. WHO (1986). Epidemiology and control of African trypanosomiasis. WHO Technical Report Series, 739.
48. WHO (1998). Control and surveillance of African trypanosomiasis, WHO, Geneva.
49. WHO (2006). Human African trypanosomiasis (sleeping sickness): epidemiological update. Weekly Epidemiological Report, 8, 71-80.
50. WHO (2007). Recommendations of the informal consultation on issues for clinical product development for human African trypanosomiasis. WHO/CDS/NTD/IDM/2007.1. Geneva, Switzerland.